The Pharma Letter » Biosimilars
The Pharma Letter » Biosimilars
5 FOLLOWERS
Scan through our blog and get to know about biosimilars. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment, and analysis for the pharmaceutical, biotechnology, and generics sectors of the healthcare industry, backed by a team of respected writers with many years of experience in the field.
Data on clinical trials become more accessible in Europe
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website
Growing admirers for Sibylla’s tech targeting ‘paradigm shift in drug design’
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website
US crackdown on Chinese biotech opens opportunities for Indian companies
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website
Antifungal specialist raises $81 million in series B round
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website
RevOpsis and Kemwell to work together on wet AMD products
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website
Antisense setback for partners Biogen and Ionis
The Pharma Letter » Biosimilars
by
3M ago
..read more
Visit website
Even without weight loss, Wegovy appears to protect the heart
The Pharma Letter » Biosimilars
by
3M ago
..read more
Visit website
Next-gen hemophilia A treatment scores hit in Phase III trial
The Pharma Letter » Biosimilars
by
3M ago
..read more
Visit website
Updated US bill to restrict Chinese biotechs provides more time to cut ties
The Pharma Letter » Biosimilars
by
4M ago
..read more
Visit website
Astellas and Pfizer outline insights planned for ASCO 2024
The Pharma Letter » Biosimilars
by
4M ago
..read more
Visit website

Follow The Pharma Letter » Biosimilars on FeedSpot

Continue with Google
Continue with Apple
OR